Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 10 versus OPTOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 10 versus OPTOMYCIN.
BLEPH-10 vs OPTOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydrofolate, thereby inhibiting bacterial folic acid synthesis and exerting bacteriostatic activity.
Optomycin is a semi-synthetic glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transpeptidation and cross-linking.
Instill 1-2 drops into the conjunctival sac every 3-4 hours, initially up to every 2 hours for severe infections.
1.5 mg/kg IV every 8 hours; alternatively, 5-7 mg/kg IV daily.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes in patients with normal renal function; prolonged in renal impairment.
3-5 hours (terminal half-life); prolonged to 10-20 hours in renal impairment.
Renal excretion of unchanged drug accounts for approximately 50-70% of the dose; biliary/fecal excretion is minimal (<10%).
Renal: 75-90% unchanged; biliary: 5-10%; fecal: <5%.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination